{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.28","upperLimit":"17.22","value":"10.61"},{"groupId":"OG001","lowerLimit":"5.59","upperLimit":"10.18","value":"7.46"},{"groupId":"OG002","lowerLimit":"5.52","upperLimit":"15.74","value":"10.15"},{"groupId":"OG003","lowerLimit":"4.11","upperLimit":"12.32","value":"9.46"},{"groupId":"OG004","lowerLimit":"8.61","upperLimit":"22.24","value":"13.57"},{"comment":"NA: not estimable due to the insufficient number of participants with events","groupId":"OG005","lowerLimit":"4.80","upperLimit":"NA","value":"9.56"},{"groupId":"OG006","lowerLimit":"12.42","upperLimit":"43.93","value":"20.76"},{"comment":"NA: not estimable due to the insufficient number of participants with events","groupId":"OG007","lowerLimit":"2.07","upperLimit":"NA","value":"4.14"},{"groupId":"OG008","lowerLimit":"13.54","upperLimit":"43.40","value":"25.95"},{"groupId":"OG009","lowerLimit":"12.85","upperLimit":"34.76","value":"21.36"},{"groupId":"OG010","lowerLimit":"11.63","upperLimit":"23.82","value":"16.79"},{"groupId":"OG011","lowerLimit":"15.24","upperLimit":"30.52","value":"21.36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"31"},{"groupId":"OG009","value":"32"},{"groupId":"OG010","value":"100"},{"groupId":"OG011","value":"60"}],"units":"Participants"}],"description":"Time from start of treatment to the date of death due to any cause. If the patient was alive at the date of the analysis cut-off or lost to follow-up, then OS was censored at the last contact date prior to data cut-off date.\n\nThe Kaplan-Meier method was used to estimate OS, and the median OS, along with 95% confidence intervals, was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG000","title":"Cohort 1a: Pre-treated Patients With MET GCN ≥ 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 6 and \\< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)","id":"OG001","title":"Cohort 1b: Pre-treated Patients With MET GCN ≥ 6 and < 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 4 and \\< 6 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG002","title":"Cohort 2: Pre-treated Patients With MET GCN ≥ 4 and < 6 (2/3L)"},{"description":"Pre-treated patients with MET GCN \\< 4 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG003","title":"Cohort 3: Pre-treated Patients With MET GCN < 4 (2/3L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG004","title":"Cohort 4: Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)","id":"OG005","title":"Cohort 5a: Treatment-naïve Patients With MET GCN ≥10 (1L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)","id":"OG006","title":"Cohort 5b: Treatment-naïve Patients With MET Mutation Regardless of MET GCN (1L)"},{"description":"Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)","id":"OG007","title":"Cohort 6.1 (Expansion of Cohort 1a): Pre-treated Patients MET GCN ≥ 10 Without MET Mutation (2L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)","id":"OG008","title":"Cohort 6.2 (Expansion of Cohort 4): Pre-treated Patients With MET Mutation (2L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)","id":"OG009","title":"Cohort 7 (Expansion of Cohort 5b): Treatment-naïve With MET Mutation Regardless of MET GCN (1L)"},{"description":"All pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L). (Participants from Cohort 4 and Cohort 6.2)","id":"OG010","title":"Cohort 4 + Cohort 6.2: All Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"All treatment naive patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as first line (1L) (Participants from Cohort 5b and Cohort 7)","id":"OG011","title":"Cohort 5b + Cohort 7: All Treatment-naive With MET Mutation Regardless of MET GCN (1L)"}],"paramType":"MEDIAN","populationDescription":"FAS, including all subjects who received at least one dose of capmatinib.","reportingStatus":"POSTED","timeFrame":"Up to approximately 6 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}